Wellnx Life Sciences Participates In ERSP Forum

ERSP found that WellNx demonstrated  Aminovol provides doses of essential, non-essential and branched chain amino acids (i.e., leucine and valine), but determined that the marketer’s representation  that the combination  of Aminovol,  XTEND24  and AbsorbMax “…keep[s] your muscles  anabolic  and anti -catabolic  all day long ” was a claim  of specific  performance  that would reasonably be relied on by consumers and was not supported.

ERSP did not dispute that the marketer has provided evidence demonstrating that the ingredients in Nitro T3 have a stimulatory effect on testosterone production, but concluded that claims that the product “maximized” testosterone and “minimize[d] estrogen, DHT and cortisol” were not adequately substantiated.

ERSP agreed with the marketer that in its advertised context and in the absence of any consumer perception evidence indicating otherwise, the claim that Mass System is the “…the ultimate supplement stack …” would be understood as a statement of puffery.

ERSP recommended removing the term “unprecedented” from the claim that the “Cell Volumization Blast Stack is designed to increase cell volumization, delivering unprecedented gains in muscle size and strength and allowing to smash through training plateaus!” and recommended that the claim that “the combination of creatine alpha-ketoglutarate and glutamine alpha-ketoglutarate” as contained in Anavol “pull in more water than ever” be modified or discontinued .ERSP also recommended that when revising its Website description of Aminovol, the marketer remove exaggerated product performance claims, for example that users will “….lift more weight every time you enter the gym.”

ERSP agreed with the marketer that the results demonstrated the claims of general efficacy on a test preparation similar to Nitro T3 on muscle attributes and testosterone in strength-trained athletes. In the absence of any reliable data to rebut the claim, ERSP determined that the claim “More testosterone + More Nitric Oxide = More Muscle Fast” was substantiated.

Although the uniqueness claims regarding Anavol and Aminovol may be appropriate, ERSP recommended the marketer discontinue its unqualified superiority claims with respect to product efficacy for both products. Similarly, ERSP concluded that WellNx provided a reasonable basis for exclusivity claims for Nitro T3 but determined that claims of unqualified performance superiority be discontinued or modified.

Finally, regarding the testimonial claim, ERSP was concerned that the typicality disclosure at the bottom of the advertisement was not clear and conspicuous and added that unless Anavol was the sole supplementary source of the muscle gain, it should be disclosed that the consumer used other muscle-building supplements.

The   company,   in   it’s   marketer   statement   said   “Wellnx   will   closely   consider   ERSP’s recommendations on its claims in future advertising.   Wellnx is a proponent of the industry self- regulatory process and welcomes the opportunity to participate in the ERSP.”